Homepage Bottom Left
-
CHS 5-year strategic framework officially launched!
The CHS is pleased to share its brand new five-year strategic framework following an extensive strategic planning exercise held in 2020. The strategy is expressed...
-
UPDATED Access to Hemlibra: Decisions from provincial/territorial governments expected in coming weeks
On May 25, 2021, Canadian Blood Services (CBS) released its report on emicizumab (Hemlibra) to the provincial/territorial (P/T) Ministers of Health (except Quebec), recommending eligibility...
-
CBS recommends emicizumab (Hemlibra) to Ministers of Health
On May 25, 2021, Canadian Blood Services (CBS) released its recommendation on emicizumab (Hemlibra) to the provincial/territorial Ministers of Health. CBS recommends that emicizumab be listed...
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
The World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines
April 12, 2021 — Please see the World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines: www1.wfh.org/docs/website/en/News/WFH-EHC-Statement-on-EMA-April2021.pdf The key...